Role of Postoperative Radiotherapy in the Management for Resected NSCLC - Decision Criteria in Clinical Routine Pre- and Post-LungART.

Süveg, Krisztian; Le Pechoux, Cecile; Faivre-Finn, Corinne; Putora, Paul M.; De Ruysscher, Dirk; Widder, Joachim; Van Houtte, Paul; Troost, Esther G C; Slotman, Ben J; Ramella, Sara; Pöttgen, Christoph; Peeters, Stephanie T H; Nestle, Ursula; McDonald, Fiona; Dziadziuszko, Rafal; Belderbos, José; Ricardi, Umberto; Manapov, Farkhad; Lievens, Yolande; Geets, Xavier; ... (2021). Role of Postoperative Radiotherapy in the Management for Resected NSCLC - Decision Criteria in Clinical Routine Pre- and Post-LungART. Clinical lung cancer, 22(6), pp. 579-586. Elsevier 10.1016/j.cllc.2021.08.007

[img] Text
1-s2.0-S1525730421002114-main.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (595kB) | Request a copy

BACKGROUND

The role of postoperative radiation therapy (PORT) in stage III N2 NSCLC is controversial. We analyzed decision-making for PORT among European radiation oncology experts in lung cancer.

METHODS

Twenty-two experts were asked before and after presentation of the results of the LungART trial to describe their decision criteria for PORT in the management of pN+ NSCLC patients. Treatment strategies were subsequently converted into decision trees and analyzed.

RESULTS

Following decision criteria were identified: extracapsular nodal extension, incomplete lymph node resection, multistation lymph nodes, high nodal tumor load, poor response to induction chemotherapy, ineligibility to receive adjuvant chemotherapy, performance status, resection margin, lung function and cardiopulmonary comorbidities. The LungART results had impact on decision-making and reduced the number of recommendations for PORT. The only clear indication for PORT was a R1/2 resection. Six experts out of ten who initially recommended PORT for all R0 resected pN2 patients no longer used PORT routinely for these patients, while four still recommended PORT for all patients with pN2. Fourteen experts used PORT only for patients with risk factors, compared to eleven before the presentation of the LungART trial. Four experts stated that PORT was never recommended in R0 resected pN2 patients regardless of risk factors.

CONCLUSION

After presentation of the LungART trial results at ESMO 2020, 82% of our experts still used PORT for stage III pN2 NSCLC patients with risk factors. The recommendation for PORT decreased, especially for patients without risk factors. Cardiopulmonary comorbidities became more relevant in the decision-making for PORT.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Radiation Oncology

UniBE Contributor:

Putora, Paul Martin

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1525-7304

Publisher:

Elsevier

Language:

English

Submitter:

Beatrice Scheidegger

Date Deposited:

13 Oct 2021 08:47

Last Modified:

21 Nov 2021 00:13

Publisher DOI:

10.1016/j.cllc.2021.08.007

PubMed ID:

34538585

Uncontrolled Keywords:

Adjuvant Decision tree Decision-making NSCLC Radiotherapy

BORIS DOI:

10.48350/159640

URI:

https://boris.unibe.ch/id/eprint/159640

Actions (login required)

Edit item Edit item
Provide Feedback